Brief: Avantor Q2 Adjusted EPS USD 0.24 Vs. IBES Estimate USD 0.25

Avantor

01/08/2025 11:05

Overview

Avantor Q2 sales of $1.68 bln, decrease of 1%

Adjusted EPS of $0.24 missed analyst expectations, per LSEG data

Emmanuel Ligner to succeed Michael Stubblefield as CEO on Aug 18

Outlook

Avantor highlights resilience amid regulatory and commercial challenges

Avantor sees strength in core monoclonal antibody platform

Result Drivers

LABORATORY SOLUTIONS - Segment delivered sequential revenue growth due to improvement initiatives, per CEO Michael Stubblefield

BIOSCIENCE PRODUCTION - Revenue grew sequentially, impacted by planned maintenance and regulatory challenges at key accounts

CONTRACT EXTENSIONS - Secured major extensions with leading pharma companies, reinforcing customer relationships

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
$1.68 bln
$1.68 bln (18 Analysts)
Q2 Adjusted EPS
Miss
$0.24
$0.25 (19 Analysts)
Q2 Net Income
$64.70 mln
Q2 Gross Profit
$554.10 mln
Q2 Operating Income
$128.80 mln
Q2 Pretax Profit
$81.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 13 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Avantor Inc is $15.25, about 11.9% above its July 31 closing price of $13.44

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nPn5YBxvGa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)